Literature DB >> 7855939

Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.

H E Wegner1, H H Knispel, R Klän, T Meier, K Miller.   

Abstract

Recent experimental work has demonstrated that nitric oxide (NO) is the neurotransmitter responsible for cavernous smooth muscle relaxation. Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results. We performed a single-blind cross-over trial in 20 patients with erectile dysfunction of mixed etiology comparing prostaglandin E1 (PGE1) to SIN-1 at two different dosages (1 and 2 mg, respectively) in order to determine the effectiveness of SIN-1. PGE1 always achieved the best response, SIN-1 performed statistically significantly poorer irrespective of the dosage used. There were only a few side effects with no significant difference. SIN-1 is not a useful alternative to PGE1 in the treatment of erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855939     DOI: 10.1159/000282674

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

Review 1.  Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature.

Authors:  H E Wegner; H H Knispel; T Meier; R Klän; K Miller
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 2.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.